The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in BRCA1/2 Mutation Carriers & Controls


Condition: Prostate Cancer in BRCA1 and BRCA2 Carriers

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT00261456

Sponsor: Institute of Cancer Research, United Kingdom

Phase:

Eligibility:

  • Age: minimum 40 Years maximum 69 Years
  • Gender: Male

Inclusion Criteria:

  • Male carriers of a known pathogenic BRCA1/2 mutations or men testing negative for a known BRCA1/2 mutation in their family
  • Aged between 40-69 years old
  • WHO performance status 0-2
  • No previous history of prostate cancer
  • No previous prostate biopsy for raised PSA
  • Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule
  • Fully informed, written consent according to ICH/EU GCP and national/local regulations before subject registration.

Exclusion Criteria:

  • Previous cancer with terminal prognosis of less than 5 years
  • Previous prostate cancer

View trial on ClinicalTrials.gov